

Michael W Deininger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3825963/publications.pdf>

Version: 2024-02-01

139
papers

17,479
citations

50170

46
h-index

14156

128
g-index

151
all docs

151
docs citations

151
times ranked

14944
citing authors

#	ARTICLE	IF	CITATIONS
1	MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β 2-chain cytokine receptor endocytosis. <i>Blood</i> , 2022, 139, 761-778.	0.6	7
2	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. <i>Journal of Hematology and Oncology</i> , 2022, 15, 1.	6.9	33
3	Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. <i>Blood Reviews</i> , 2022, 56, 100968.	2.8	16
4	Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. <i>Blood Advances</i> , 2022, 6, 5750-5762.	2.5	20
5	Genetic complexity of chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1031-1045.	0.6	4
6	Imatinib, cheese and migraines. <i>Leukemia and Lymphoma</i> , 2021, 62, 746-748.	0.6	2
7	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. <i>HemaSphere</i> , 2021, 5, e536.	1.2	11
8	Eradicating residual chronic myeloid leukaemia: basic research lost in translation. <i>Lancet Haematology</i> , 2021, 8, e101-e104.	2.2	2
9	Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 3176-3187.	3.3	8
10	SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021, 2, 266-287.	2.6	37
11	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. <i>Blood</i> , 2021, 138, 2042-2050.	0.6	95
12	Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. <i>Blood Reviews</i> , 2021, 49, 100825.	2.8	62
13	Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis. <i>Cancers</i> , 2021, 13, 4863.	1.7	1
14	Femoral Heads from Total Hip Arthroplasty as a Source of Adult Hematopoietic Cells. <i>Acta Haematologica</i> , 2021, 144, 458-464.	0.7	1
15	A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM). <i>Blood</i> , 2021, 138, 3642-3642.	0.6	1
16	Effective Control of Advance Systemic Mastocytosis with Avapritinib: Mutational Analysis from the Explorer Clinical Study. <i>Blood</i> , 2021, 138, 318-318.	0.6	16
17	A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with Myelofibrosis Refractory or Intolerant to JAK Inhibitors. <i>Blood</i> , 2021, 138, 143-143.	0.6	5
18	Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. <i>Nature Medicine</i> , 2021, 27, 2183-2191.	15.2	78

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. <i>Nature Medicine</i> , 2021, 27, 2192-2199.	15.2	79
20	Trident cold atmospheric plasma blocks three cancer survival pathways to overcome therapy resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
21	Imatinib is not a potent anti-SARS-CoV-2 drug. <i>Leukemia</i> , 2020, 34, 3085-3087.	3.3	36
22	No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group. <i>Leukemia and Lymphoma</i> , 2020, 61, 2821-2830.	0.6	0
23	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	2.2	56
24	Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. <i>Nature Medicine</i> , 2020, 26, 1852-1858.	15.2	104
25	Pregnancy outcomes in patients treated with bosutinib. <i>International Journal of Hematologic Oncology</i> , 2020, 9, IJH26.	0.7	17
26	Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 3507-3510.	0.6	2
27	Declaration of Bcr-Abl1 independence. <i>Leukemia</i> , 2020, 34, 2827-2836.	3.3	15
28	Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature. <i>Haematologica</i> , 2020, 105, 2795-2804.	1.7	15
29	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions. <i>Blood Cancer Discovery</i> , 2020, 1, 48-67.	2.6	30
30	Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. <i>Leukemia</i> , 2020, 34, 2981-2991.	3.3	8
31	Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells. <i>Leukemia</i> , 2020, 34, 1679-1683.	3.3	6
32	Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial. <i>Blood</i> , 2020, 136, 41-42.	0.6	27
33	Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study. <i>Blood</i> , 2020, 136, 37-38.	0.6	10
34	Phase 1 Trial of Vodobotinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib. <i>Blood</i> , 2020, 136, 51-52.	0.6	20
35	Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1385-1415.	2.3	147
36	Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. <i>Blood</i> , 2019, 134, 867-879.	0.6	55

#	ARTICLE	IF	CITATIONS
37	BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. <i>Experimental Hematology</i> , 2019, 77, 36-40.e2.	0.2	14
38	Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. <i>Cancer Cell</i> , 2019, 36, 431-443.e5.	7.7	137
39	Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. <i>Hematological Oncology</i> , 2019, 37, 240-252.	0.8	8
40	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. <i>Haematologica</i> , 2019, 104, 1935-1949.	1.7	93
41	Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. <i>Leukemia Research</i> , 2019, 79, 38-44.	0.4	25
42	Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2651-2665.	2.9	28
43	JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. <i>Blood</i> , 2019, 134, 2388-2398.	0.6	25
44	deeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?. <i>Clinical Cancer Research</i> , 2019, 25, 6561-6563.	3.2	4
45	The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. <i>Blood Advances</i> , 2019, 3, 2949-2961.	2.5	29
46	Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations. <i>Blood Advances</i> , 2019, 3, 952-955.	2.5	8
47	CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. <i>EBioMedicine</i> , 2019, 50, 111-121.	2.7	14
48	Nuclear Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. <i>Clinical Cancer Research</i> , 2019, 25, 2323-2335.	3.2	24
49	Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 16, 217-225.	1.7	14
50	Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019, 134, 4223-4223.	0.6	1
51	Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective. <i>Leukemia</i> , 2018, 32, 2049-2054.	3.3	4
52	Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. <i>Blood</i> , 2018, 132, 393-404.	0.6	392
53	Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 231-237.	0.8	356
54	Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1500-1537.	2.3	41

#	ARTICLE	IF	CITATIONS
55	Functional genomic landscape of acute myeloid leukaemia. <i>Nature</i> , 2018, 562, 526-531.	13.7	907
56	Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion. <i>Leukemia</i> , 2018, 32, 2399-2411.	3.3	39
57	Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial. <i>Blood</i> , 2018, 132, 3005-3005.	0.6	7
58	Pregnancy Outcomes in Patients Treated with Bosutinib. <i>Blood</i> , 2018, 132, 1729-1729.	0.6	6
59	Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial. <i>Blood</i> , 2018, 132, 1734-1734.	0.6	5
60	Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM). <i>Blood</i> , 2018, 132, 351-351.	0.6	15
61	Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial. <i>Blood</i> , 2018, 132, 792-792.	0.6	8
62	Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies. <i>Blood</i> , 2018, 132, 559-559.	0.6	14
63	Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia. <i>Blood</i> , 2018, 132, 350-350.	0.6	5
64	Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib. <i>Oncotarget</i> , 2018, 9, 17889-17894.	0.8	1
65	Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey. <i>Blood</i> , 2018, 132, 5843-5843.	0.6	0
66	Drug-Free Macromolecular Therapeutics Induce Apoptosis in Cells Isolated from Patients with B Cell Malignancies with Enhanced Apoptosis Induction By Pretreatment with Gemcitabine. <i>Blood</i> , 2018, 132, 4426-4426.	0.6	1
67	Combining Dasatinib and AC220 Reduces Stroma-Based pSTAT5Y694 in FLT3-ITD+ AML and Overcomes FLT3 TKI Resistance. <i>Blood</i> , 2018, 132, 2641-2641.	0.6	0
68	Synergistic Effect of Imatinib and Ruxolitinib in a Patient with JAK2V617F positive Myelofibrosis and Concomitant BCR-ABL1 positive Chronic Myeloid Leukemia. <i>Blood</i> , 2018, 132, 5482-5482.	0.6	0
69	Comorbidities Are Major Drivers of Overall Survival of Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2018, 132, 5521-5521.	0.6	0
70	Molecular Alterations in Chronic Myelomonocytic Leukemia Monocytes: Transcriptional and Methylation Profiling. <i>Blood</i> , 2018, 132, 3889-3889.	0.6	0
71	Disease Characteristics and Treatment of Adult Langerhans Cell Histiocytosis: A Single Center Experience. <i>Blood</i> , 2018, 132, 4315-4315.	0.6	1
72	Genotypic Representation of Myelodysplastic/Myeloproliferative Neoplasms in Nrg, Nrg-3GS and Srg-W41 Mice with Transgenic Expression of Human Cytokines. <i>Blood</i> , 2018, 132, 2038-2038.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 917-927.	13.9	926
74	Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1311-1318.	1.2	14
75	miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response. <i>Blood</i> , 2017, 129, 3074-3086.	0.6	57
76	Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?. <i>Expert Review of Hematology</i> , 2017, 10, 659-674.	1.0	16
77	Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1519-1529.	1.7	36
78	Minimal Residual Disease Eradication in CML: Does It Really Matter?. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 495-505.	1.2	5
79	Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 589-612.	0.9	125
80	Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. <i>ChemMedChem</i> , 2016, 11, 850-861.	1.6	23
81	NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1505-1512.	2.3	57
82	Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 341-349.e1.	0.2	11
83	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 612-621.	5.1	214
84	Chronic myeloid leukemia: reminiscences and dreams. <i>Haematologica</i> , 2016, 101, 541-558.	1.7	92
85	Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. <i>Blood</i> , 2016, 127, 703-712.	0.6	87
86	New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape. <i>Clinical Cancer Research</i> , 2016, 22, 1037-1047.	3.2	13
87	A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2441-2444.	0.6	20
88	MS4A3: A New Player in Leukemic Stem Cell Survival in Chronic Myeloid Leukemia. <i>Blood</i> , 2016, 128, 934-934.	0.6	7
89	Molecular monitoring in CML and the prospects for treatment-free remissions. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 257-263.	0.9	20
90	shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. <i>Blood</i> , 2015, 125, 1772-1781.	0.6	41

#	ARTICLE	IF	CITATIONS
91	The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. <i>Blood</i> , 2015, 126, 1551-1554.	0.6	151
92	Diagnosing and Managing Advanced Chronic Myeloid Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e381-e388.	1.8	19
93	Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. <i>Experimental Hematology</i> , 2015, 43, 537-545.e11.	0.2	10
94	Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E5381-90.	3.3	93
95	Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 4210-4218.	0.8	355
96	Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. <i>Nature Medicine</i> , 2015, 21, 71-75.	15.2	106
97	Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. <i>Leukemia</i> , 2015, 29, 586-597.	3.3	111
98	MS4A3 Improves Imatinib Response and Survival in BCR-ABL1 Primary TKI Resistance and in Blastic Transformation of Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 14-14.	0.6	2
99	Circulating Cytokines and Markers of Iron Metabolism in Myelofibrosis Patients Treated with Momelotinib: Correlatives from the Ym-387-II Study. <i>Blood</i> , 2015, 126, 1600-1600.	0.6	2
100	Imatinib 800mg daily induces deeper molecular responses than imatinib 400mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2014, 164, 223-232.	1.2	56
101	Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. <i>Genome Biology</i> , 2014, 15, 461.	3.8	23
102	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442.	7.7	292
103	Chronic Myelogenous Leukemia, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1590-1610.	2.3	49
104	BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. <i>Blood</i> , 2014, 124, 3260-3273.	0.6	20
105	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. <i>Blood</i> , 2014, 124, 3135-3135.	0.6	43
106	High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib. <i>Blood</i> , 2014, 124, 3153-3153.	0.6	1
107	CNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition. <i>Blood</i> , 2014, 124, 3567-3567.	0.6	3
108	Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials. <i>Blood</i> , 2014, 124, 4552-4552.	0.6	8

#	ARTICLE	IF	CITATIONS
109	Achieving Early Landmark Response Is Predictive of Outcomes in Heavily Pretreated Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib. <i>Blood</i> , 2014, 124, 518-518.	0.6	1
110	Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML). <i>Blood</i> , 2014, 124, 519-519.	0.6	30
111	Response Monitoring, Tolerability, and Effectiveness of Imatinib Treatment for Chronic Myeloid Leukemia in a Retrospective Research Database. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1113-1121.	2.3	6
112	Limited Efficacy of BMS-911543 in a Murine Model of JAK2V617F Myeloproliferative Neoplasm. <i>Blood</i> , 2014, 124, 5572-5572.	0.6	0
113	Effect of a TNF α Blocker and Peginfra on Polycythemia Vera Clonal Hematopoiesis and Suppressed Normal Dormant Hematopoiesis. <i>Blood</i> , 2014, 124, 1820-1820.	0.6	0
114	BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. <i>Blood</i> , 2013, 121, 489-498.	0.6	187
115	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013, 122, 872-884.	0.6	1,743
116	KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2013, 73, 5775-5786.	0.4	22
117	Direct Contact With Bone Marrow Stromal Cells Protects CML Progenitors From Imatinib Through Cytoplasmic Stabilization Of β -Catenin. <i>Blood</i> , 2013, 122, 3982-3982.	0.6	17
118	A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2012, 120, 3898-3905.	0.6	154
119	A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. <i>New England Journal of Medicine</i> , 2012, 366, 799-807.	13.9	1,738
120	Pushing the limits of targeted therapy in chronic myeloid leukaemia. <i>Nature Reviews Cancer</i> , 2012, 12, 513-526.	12.8	260
121	Zebrafish screen identifies novel compound with selective toxicity against leukemia. <i>Blood</i> , 2012, 119, 5621-5631.	0.6	138
122	What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?. <i>Leukemia Research</i> , 2012, 36, 253-261.	0.4	13
123	TNF α facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. <i>Blood</i> , 2011, 118, 6392-6398.	0.6	227
124	Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. <i>Journal of Clinical Investigation</i> , 2011, 121, 396-409.	3.9	661
125	Development of an Effective Therapy for Chronic Myelogenous Leukemia. <i>Cancer Journal (Sudbury, Tj)</i> ETQq1 1 0.784314 rgBT /Overl	1.0	37
126	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 553-561.	3.0	362

#	ARTICLE	IF	CITATIONS
127	Curing CML with imatinibâ€”a dream come true?. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 127-128.	12.5	31
128	CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. <i>Blood</i> , 2010, 115, 5232-5240.	0.6	216
129	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009, 27, 6041-6051.	0.8	1,188
130	International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.. <i>Blood</i> , 2009, 114, 1126-1126.	0.6	358
131	SGX393 inhibits the CML mutant Bcr-Abl ^{T315I} and preempts <i>in vitro</i> resistance when combined with nilotinib or dasatinib. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5507-5512.	3.3	84
132	Persistent LYN Signaling in Imatinib-Resistant, BCR-ABLâ€”Independent Chronic Myelogenous Leukemia. <i>Journal of the National Cancer Institute</i> , 2008, 100, 908-909.	3.0	26
133	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , 2006, 108, 28-37.	0.6	1,117
134	Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)â€”based mutagenesis screen: high efficacy of drug combinations. <i>Blood</i> , 2006, 108, 2332-2338.	0.6	368
135	Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib. <i>Molecular and Cellular Biology</i> , 2006, 26, 6082-6093.	1.1	192
136	High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naïve patients: correlation with clonal cytogenetic evolution but not response to therapy. <i>Blood</i> , 2005, 106, 2128-2137.	0.6	297
137	The development of imatinib as a therapeutic agent for chronic myeloid leukemia. <i>Blood</i> , 2005, 105, 2640-2653.	0.6	1,137
138	Clonal Cytogenetic Abnormalities in Philadelphia Chromosome Negative Cells in Chronic Myeloid Leukemia Patients Treated with Imatinib. <i>Leukemia and Lymphoma</i> , 2004, 45, 2197-2203.	0.6	71
139	The Presence of Typical and Atypical BCR-ABL Fusion Genes in Leukocytes of Normal Individuals: Biologic Significance and Implications for the Assessment of Minimal Residual Disease. <i>Blood</i> , 1998, 92, 3362-3367.	0.6	413